AI Innovation and Strategic DAM Deployments Fuel Record First Half for Bynder
24.7.2024 16:00:00 EEST | Business Wire | Press release
Bynder, a global leader in enterprise digital asset management (DAM), has revealed how the accelerated adoption of the company’s AI-powered solutions and strategic DAM deployments have driven record growth in the first half of 2024.
More than 350 customers have adopted Bynder’s enhanced AI Search Experience since its launch nine months ago, and through the solution, more than 30 million images have been processed. Bynder, which currently has over 150 million active assets on its platform, also reported that in the first half of the year, it has seen a 20% year-on-year increase in the delivery of assets to connected systems. With assets delivered 113 billion times in the first half of the year, this shows that Bynder’s customers are continuing to leverage content as a strategic differentiator to deliver exceptional content experiences.
Bynder first integrated AI into its platform in 2016, demonstrating the company’s long-term commitment well before it became mainstream. Since then, Bynder has accelerated its efforts by acquiring an AI company and launching AI Search Experience, continually enhancing its AI capabilities and giving customers governance and control over how AI is used in their organizations and on their own terms.
Since the launch of Bynder’s AI Search Experience, many of Bynder's customers have adopted the solution, reinforcing the trend that AI is increasingly viewed as a strategic tool for marketers seeking to streamline content operations and improve customer experience. This trend validates Bynder's approach to AI, demonstrating the need to harness AI responsibly to deliver tangible benefits to its customers.
Bynder’s AI-powered DAM platform is pivotal in supporting go-to-market operations and the adoption of AI within content operations has driven the rapid uptake of Bynder’s AI Search Experience. This solution is customer-inspired and enables teams to maximize asset reuse, save resources, reduce time spent searching for assets, and automatically eliminate duplicates.
The benefits of the solution were evidenced at Bynder’s recent customer Spotlight Awards where brands such as Viator, Les Mills and Inspire Brands were recognized for their excellence in innovation, creating compelling value and return on investment when it comes to the implementation and use of Bynder DAM.
By leveraging AI-powered recommendations and filtering options, Inspire Brands was able to quickly locate and distribute relevant assets across its portfolio of sub-brands. This new level of findability has promoted content reuse within the organization and increased the value of the assets that the company invests in.
Cliff Crosbie, Head of AI Strategies at Bynder, said: “It’s great to see that our ongoing innovation and market leadership in AI has continued to drive growth in the first half of this year, along with our strategic DAM deployments which have both become invaluable solutions for our customers. The digital landscape continues to evolve faster than ever, so it’s our aim to implement AI responsibly to help drive scale and efficiency and we’re looking forward to bringing the next phase of our AI enhancements to market very soon.”
As a result of the company’s accelerated growth, Bynder has appointed Ann-Michèle Verheyden as its new Chief Legal Officer. Ann-Michèle brings extensive experience in SaaS, IP and privacy, supporting Bynder’s position and investment in AI where she will be building a robust compliance framework enabling businesses to navigate the complexities of AI-driven technology while mitigating risk.
Richard Heitmann also joins Bynder as its new Chief Marketing Officer. Richard brings a wealth of experience from high-growth startups like Aspera and enterprise software experience from IBM. Richard’s expertise will help drive further growth and bring Bynder’s platform innovations to the market.
Looking forward to the second half of the year, Bynder will host its inaugural customer event, Bynder Connect, in September in Amsterdam. The event will bring together industry leaders to share insights, launch new innovations, and celebrate successes with its customers.
For more information on Bynder’s AI-powered DAM, please visit: https://www.bynder.com/en/solutions/initiatives/ai-automation/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724434819/en/
Contacts
Manisha Mehta / manisha.mehta@bynder.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom